Trial Profile
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Lenabasum (Primary)
- Indications Dermatomyositis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Corbus Pharmaceuticals
- 01 Oct 2022 Results published in the Journal of Investigative Dermatology
- 04 Jun 2022 Results of retrospective analysis of this study assessing the correlations between CDASI-A, quality of life (QoL), and biomarkers of disease activity, presented at the 23rd Annual Congress of the European League Against Rheumatism.
- 05 Jun 2021 Results assessing long-term safety and efficacy in Dermatomyositis subjects presented at the 22nd Annual Congress of the European League Against Rheumatism